Recent share performance check

MannKind (MNKD) has drawn fresh attention after a sharp move in its stock price, with shares last closing at $3.52. Investors are now weighing how recent returns compare with the company’s fundamentals.

The recent 1 day share price return of 4.76% comes after a mixed period, with the stock up 34.87% over 90 days and 23.08% over 30 days. However, the year to date share price return and 1 year total shareholder return are both down sharply, which points to short term momentum rebuilding after a weaker longer term experience for holders.

If MannKind's move has you rethinking your watchlist, this is a useful moment to scan for other health related opportunities through our screener of 40 healthcare AI stocks

With MannKind still loss making on US$360.783 million of revenue and trading at US$3.52, yet sitting at a discount to some analyst and intrinsic value estimates, is this stock mispriced, or is the market already factoring in its future growth?

Most Popular Narrative: 50.9% Undervalued

Against MannKind's last close at $3.52, the most followed valuation narrative points to a fair value of about $7.17, putting a big spotlight on the long term royalty and inhaled-therapy story behind that gap.

Afrezza's continued double-digit prescription growth, international expansion efforts, upcoming pediatric indication launch, and a broadened salesforce footprint are set to accelerate market penetration amid a rising global diabetes burden and an aging population, directly supporting revenue and earnings growth.

Curious what revenue path, margin lift, and future earnings power are baked into that fair value, and how they tie into treprostinil royalties and pediatric insulin timing.

Result: Fair Value of $7.17 (UNDERVALUED)

However, that story can change quickly if Tyvaso DPI royalties face pressure from United Therapeutics' soft mist inhaler plans or if Afrezza remains a niche product with limited uptake.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With mixed signals across valuation, royalties, and product uptake, this is the moment to look at the numbers yourself and decide where you stand. Start with our breakdown of 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with a single stock. Broaden your watchlist with focused ideas that line up with your risk tolerance, income needs, and style.

• Target potential upside with a curated list of screener containing 22 high quality undiscovered gems that many investors may not be watching yet.
• Prioritise resilience by scanning 65 resilient stocks with low risk scores built around companies with lower risk scores.
• Strengthen portfolio quality by reviewing the solid balance sheet and fundamentals stocks screener (46 results) before capital moves elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.